GEWEBESELEKTIVE TRANSGENEXPRESSION

European patent · EP3607073 · In force

Register entry

Publication number
EP3607073
Application number
EP18781685
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 3, 2018
Published
Feb 12, 2020
Granted
Jun 5, 2024
Protection ends at the latest
Apr 2, 2038
Next annual fee due
Apr 30, 2027
IPC classes
C12N 15/63 (2006.01)
A01K 67/027 (2024.01)
C12Q 1/68 (2018.01)
Priority
US 201762480998 P 03.04.2017
PCT application
PCT/US2018/025940 03.04.2018
PCT publication
WO2018/187363 11.10.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. Apr 16, 2025

    Change

    Published in Swissreg on 16.04.2025

  4. Jul 17, 2024

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 17.07.2024

  5. Jun 5, 2024

    Granted

    Published in Swissreg on 05.06.2024

Parties

Holder

Encoded Therapeutics, Inc.

341 Oyster Point Boulevard, South San Francisco, CA 94080, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

RAMAMOORTHI, Kartik

South San Francisco, California 94080, US

TAGLIATELA, Stephanie

South San Francisco, California 94080, US

OBERKOFLER, David

South San Francisco, California 94080, US

YOUNG, Andrew

South San Francisco, California 94080, US

CHEN, Szu-Ying

South San Francisco, California 94080, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.